Coverage
Filings
Genmab A/S announced encouraging results from its Phase 1/2 RAINFOL-01 trial for rinatabart sesutecan (Rina-S), an investigational antibody-drug conjugate (ADC), in heavily pretreated patients with advanced endometrial cancer.
| 15 Jun 2025 |
| Grant of Restricted Stock Units and Warrants to Employees in Genmab | 12 Jun 2025 |
| Transactions in Connection with Share Buy-back Program | 10 Jun 2025 |
| Transactions in Connection with Share Buy-back Program | 2 Jun 2025 |
| Genmab to Participate in a Fireside Chat at the 46th Goldman Sachs Annual Global Healthcare Conference | 27 May 2025 |